Is tofacitinib/Shangjie an analgesic?
Tofacitinib/Shangjie(Tofacitinib) is not an analgesic drug in the traditional sense. It belongs to a class of small molecule targeted immune modulators called Janus kinase (JAK) inhibitors. Many patients see a reduction in pain and joint stiffness when treated for rheumatoid arthritis or psoriatic arthritis, so it is easy to mistake tofacitinib for a pain reliever. In fact, it does not directly act on pain receptors like common non-steroidal anti-inflammatory drugs (NSAIDs) or opioids. Instead, it inhibits the JAK pathway and reduces the signaling of inflammatory cytokines, thereby fundamentally reducing the inflammatory response and indirectly relieving pain and improving function.

In clinical applications, tofacitinib is approved for the treatment of diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis, which are often accompanied by chronic inflammation and pain. Because tofacitinib can regulate the immune system and block the release of abnormal inflammatory factors, the improvement of patient symptoms is not only reduced joint swelling and intestinal inflammation, but also reduces pain. It is precisely because of this indirect analgesic effect that many patients confuse it with painkillers.
Compared with real analgesics, the mechanism of action of tofacitinib is closer to "cause treatment". It does not just cover up pain, but reduces the occurrence of pain from the root by inhibiting pathological immune responses. Therefore, its role in disease control is completely different from that of conventional analgesics. From a safety perspective, tofacitinib is not suitable for all people. It is a prescription drug that may increase the risk of infection, raise blood lipid levels, and even be linked to cardiovascular events. Therefore, during use, doctors will conduct a comprehensive assessment based on the patient's disease condition, previous medication history, and comorbidities, and will not prescribe it simply as an analgesic.
Reference materials:https://www.xeljanz.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)